Fosamax

ApprovedSmall molecule

Mylan Pharmaceuticals Inc

Fosamax is one of 136 small molecule programs targeting Cerebral Palsy. It is currently in Approved.

Indications

Total Trials

Active Trials

135

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral PalsyActive, not recruiting

Polyostotic Fibrous DysplasiaActive, not recruiting

Thyroid CancerActive, not recruiting

OsteoporosisActive, not recruiting

Spinal Cord InjuryActive, not recruiting

Cerebral PalsyPhase 3

Active, not recruiting

Polyostotic Fibrous DysplasiaPhase 2

Active, not recruiting

Thyroid CancerPreclinical

Active, not recruiting

OsteoporosisApproved

Active, not recruiting

Spinal Cord InjuryPreclinical

Active, not recruiting

Competition

Competitive Landscape

210 competitors in Thyroid Cancer

#DrugCompanyPhaseTrials

Nexavar

Bayer

Phase 3

12 2

Koselugo

AstraZeneca

Phase 3

3 3

Fosamax

Mylan Pharmaceuticals Inc

Approved

1 4

Glucophage

EMD Serono

Phase 3

2 5

Afinitor

Novartis

Phase 2

7 6

Votrient

Novartis

Phase 2

3 7

Verzenio

Eli Lilly

Phase 2

1 8

Adriamycin

Pfizer

Phase 2

1 9

Neupogen

EEastern Cooperative Oncology Group

Phase 2

3 10

Signifor

RRECORDATI GROUP

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

OSA2 trials

Fasting Study of Alendronate Sodium Tablets (70 mg) and Fosamax Tablets (70 mg)

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT01012934·110 enrolled

Fasting Study of Alendronate Sodium Tablets (10 mg) and Fosamax Tablets (10 mg)

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00983996·112 enrolled

Bone Loss1 trial

Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss

Completed·UUniversity of California, San Francisco··NCT00221312·48 enrolled

Osteoporosis1 trial

Phase IV Clinical Trial to Evaluate Efficacy and Safety of MASI BONE S (Alendronate Sodium Trihydrate) in Postmenopausal Women With Osteoporosis

Unknown status·YYonsei University·Phase 4·NCT05387200·170 enrolled

Thyroid Cancer1 trial

99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis

Completed·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·N/A·NCT02304757·142 enrolled

Spinal Cord Injury1 trial

Pilot Study of Fosamax in Spinal Cord Injury

Terminated·UUniversity of Rochester·N/A·NCT01131884·1 enrolled

4 more indications

Fasting Conditions1 trial

Alendronate Sodium 70 mg Tablet Versus Fosamax® Under Fasting Conditions.

Completed· Teva logo

Teva·Phase 1·NCT00835406·140 enrolled

Polyostotic Fibrous Dysplasia1 trial

Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome

Completed·NNational Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT00001728·40 enrolled

Outcome1 trial

Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes

Unknown status·LLabatec Pharma SA··NCT03435094·80 enrolled

Cerebral Palsy1 trial

Use of Oral Bisphosphonates in the Treatment of Osteoporosis of Non-walking Children With Cerebral Palsy

Terminated·DDepartment of Clinical Research and Innovation·Phase 3·NCT00822029·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Fosamax. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fosamax compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fosamax. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mylan Pharmaceuticals Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Mylan Pharmaceuticals Inc

Fosamax

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

OSA2 trials

Bone Loss1 trial

Osteoporosis1 trial

Thyroid Cancer1 trial

Spinal Cord Injury1 trial

Fasting Conditions1 trial

Polyostotic Fibrous Dysplasia1 trial

Outcome1 trial

Cerebral Palsy1 trial

References

Drug Info

Quick Facts

Related News